#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Tourette's disorder Andersen-Tawil syndrome Deafness neurosensory Hypersomnia Neuroendocrine tumour of the lung Mitochondrial encephalomyopathy Immunodeficiency common variable Immunoglobulin G4 related disease Transferrin decreased Myelodysplastic syndrome B-cell small lymphocytic lymphoma Neuroendocrine carcinoma of the skin Acquired haemophilia Penile cancer Oesophageal carcinoma More trials…

    Learn about Rare Diseases

    Ewing’s sarcoma metastatic – Life with Disease Testicular leiomyosarcoma – Diagnostics Primary immunodeficiency syndrome – Trials in Disease Familial haemophagocytic lymphohistiocytosis – Diagnostics Mastocytosis Mantle cell lymphoma stage II – Trials in Disease Systemic sclerosis pulmonary – Diagnostics Hereditary angioedema – Trials in Disease Primary hyperoxaluria – Treatment Optic glioma – Life with Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Inupadenant Nirogacestat Hydrobromide Fosfomycin L-SERINE Dexlansoprazole Plasma SILYMARIN Dopamine Hydrochloride RIVASTIGMINE Benfotiamine Ianalumab Adezunap Selexipag Oxytocin Synthetic Human Vaccinia Immunoglobulin Arrhenatherum Elatius Meclofenamate Sodium PEGZILARGINASE Anidulafungin Ethanol, Anhydrous More therapies…

    Learn about Your Condition

    Plasma cell myeloma Anaplastic thyroid cancer Colorectal cancer metastatic Exfoliation glaucoma Atrophic vulvovaginitis Renal cancer metastatic Retinal artery occlusion Chronic disease Chronic granulomatous disease Adrenogenital syndrome Acquired ATTR amyloidosis Nasopharyngeal cancer Keratosis follicular Cholecystitis acute Hepatitis B More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Crohn’s disease

  • A study to evaluate the effectiveness and safety of duvakitug in patients with moderate to severe Crohn’s disease

    Recruiting

    3 1
    Investigated Drugs:
    • Duvakitug
    Austria Belgium Bulgaria Czechia France Germany +9

  • Study of icotrokinra for adults with moderately to severely active Crohn’s disease

    Recruiting

    4 1
    Investigated Diseases:
    • Crohn’s disease
    Investigated Drugs:
    • ICOTROKINRA
    Belgium Czechia France Germany Greece Hungary +7

  • A study testing how well mirikizumab works to achieve transmural healing in patients with Crohn’s Disease

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Crohn’s disease
    Investigated Drugs:
    • Mirikizumab
    France

  • Study of MT-501 in patients with active Crohn’s Disease or Ulcerative Colitis: A Phase 2 safety and effectiveness trial

    Recruiting

    2 1
    Investigated Diseases:
    • Crohn’s disease
    • Colitis ulcerative
    Belgium Bulgaria Croatia Czechia Germany Italy +2

  • Long-term safety study of subcutaneous vedolizumab in children and adolescents with ulcerative colitis or Crohn’s disease

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Vedolizumab
    Belgium Bulgaria Denmark Ireland Italy The Netherlands +4

  • Study of tulisokibart compared to placebo in adults with moderate to severe Crohn’s disease

    Recruiting

    3 1
    Investigated Diseases:
    • Crohn’s disease
    Investigated Drugs:
    • Tulisokibart
    Austria Belgium Croatia Czechia Denmark Finland +15
Previous Page
1 2 3 4 … 16
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!